Network Meta-Analysis of ALS Therapies: Efficacy and Safety from 109 Trials

A 2025 network meta-analysis synthesizing results from 109 randomized controlled trials involving 16,353 participants with amyotrophic lateral sclerosis (ALS). The dataset, authored by Shixun Zhou and published under CC-BY-4.0, compares the efficacy and safety of pharmacological and biological interventions on functional, respiratory, and survival outcomes.

Use Cases

• Ranking therapeutic interventions for ALS based on Surface Under the Cumulative Ranking Curve (SUCRA) scores mentioned in the description
• Comparing treatment effects on the ALS Functional Rating Scale-Revised (ALSFRS-R) and forced vital capacity (FVC) outcomes
• Assessing safety profiles by analyzing serious adverse event (SAE) risks across different drug classes
• Identifying heterogeneity within therapeutic classes, such as among enzyme inhibitors, for further investigation

Strengths

• Systematic synthesis of 109 randomized controlled trials, a substantial evidence base
• Includes data from 16,353 participants, providing a large sample for analysis
• Employs a Bayesian network meta-analysis methodology for comparative effectiveness
• Registered with PROSPERO (CRD420251000672), indicating a predefined protocol

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The 117.0 KB file size suggests the dataset contains summary-level results, not individual patient data

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of trials from PubMed, EMBASE, Cochrane, and Web of Science up to February 25, 2025.

Time Range

Trials included up to February 2025.

Freshness

Last updated 2026-04-24 13:39:37; freshness should be verified

Geography

Likely global, but specific geographic coverage of included trials is not stated.